Zhaoke Ophthalmology (6622) said its presbyopia drug YUVEZZITM (carbachol/brimonidine tartrate eye drops) received regulatory approval from the Macau Government Pharmaceutical Administration on July 13, according to Ming Pao.
The group also said that in June, it obtained regulatory approval from the Hainan Provincial Medical Products Administration, allowing YUVEZZITM to be used at Boao Super Hospital as an urgently needed imported clinical drug.
Ming Pao Reported That Zhaoke Ophthalmology's YUVEZZITM Wins Macau Approval
2026-07-20 11:30:44
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
